Raghav 'RV' Sehgal

Harvard Medical School brings together the brightest minds in science and medicine to improve health and well-being for all.  With our affiliated  hospitals and research institutes, we are home to more than 12,000 faculty members and 1,600 medical and graduate students — more than twice that of any other medical school in the United States. The possibilities for mentorship and impact across a range of disciplines at HMS are unparalleled. Harvard Medical School has: ► Trained generations of doctors and researchers, pioneering new educational models and curricula to continually address emerging needs in health care ► Made impactful discoveries and fueled innovation, including life-changing new therapies for cancer, diabetes, and sickle cell disease and new knowledge addressing rising health care costs and health inequities ► Collaborated with local community organizations to improve health for vulnerable populations Our community is united in its desire to tackle complex challenges in science, medicine, and health, guided by a shared sense of purpose and a genuine passion to make a difference. 

Asima Health is a molecular diagnostics company building a fundamentally simpler foundation for frequent cancer monitoring. Our platform, Asima™ Rev, analyzes structural changes in cell-free DNA — eliminating complex, multi-step gene sequencing workflows and enabling faster, more scalable testing. We offer: • Multi-cancer capability from a single blood draw • High accuracy, as early as stage I • AI-enabled cancer staging insights • Rapid turnaround times • Simple lab-on-a-chip technology deployable in local labs Were launching with colorectal and lung cancer recurrence monitoring, with expansion planned across broader pan-cancer applications. Our mission is to make cancer monitoring more accessible, affordable, and practical for real-world patient care.

NaNotics LLC is developing a nanomedical platform – called NaNots – for treating major diseases – including a broad range of cancers and inflammatory disorders – via depletion from blood of specific molecules that drive or enable those diseases. NaNots are injected like a drug and clear their targets quickly, deeply and safely: typically >95% target depletion in < 5 minutes, without measurable toxicity. NaNotics is in the late preclinical stage; we are about to announce a collaboration with a major oncology center for a first-in-human study of NaNots against a soluble tumor-generated immune inhibitor, for treating cancer. The NaNotics team invented the NaNot technology, which is now the subject of 12 granted patents, with many more pending. NaNotics is based in Mill Valley, CA, just north of San Francisco.

Harvard Medical School brings together the brightest minds in science and medicine to improve health and well-being for all.  With our affiliated  hospitals and research institutes, we are home to more than 12,000 faculty members and 1,600 medical and graduate students — more than twice that of any other medical school in the United States. The possibilities for mentorship and impact across a range of disciplines at HMS are unparalleled. Harvard Medical School has: ► Trained generations of doctors and researchers, pioneering new educational models and curricula to continually address emerging needs in health care ► Made impactful discoveries and fueled innovation, including life-changing new therapies for cancer, diabetes, and sickle cell disease and new knowledge addressing rising health care costs and health inequities ► Collaborated with local community organizations to improve health for vulnerable populations Our community is united in its desire to tackle complex challenges in science, medicine, and health, guided by a shared sense of purpose and a genuine passion to make a difference. 

Asima Health is a molecular diagnostics company building a fundamentally simpler foundation for frequent cancer monitoring. Our platform, Asima™ Rev, analyzes structural changes in cell-free DNA — eliminating complex, multi-step gene sequencing workflows and enabling faster, more scalable testing. We offer: • Multi-cancer capability from a single blood draw • High accuracy, as early as stage I • AI-enabled cancer staging insights • Rapid turnaround times • Simple lab-on-a-chip technology deployable in local labs Were launching with colorectal and lung cancer recurrence monitoring, with expansion planned across broader pan-cancer applications. Our mission is to make cancer monitoring more accessible, affordable, and practical for real-world patient care.

Our goal is to extend healthy and active human life and minimize chronic and age-related diseases. Longevitytech.fund does pre-seed and seed-stage investments in the best of worldwide early-stage startups and university spinoffs based on our close cooperation with top scientists in the fields of aging research and rejuvenation, biotechnology, bioinformatics, agetech, and related AI. We provide an active approach with entrepreneurial help and network and commercialization support. We also provide a longevity program for our LPs. Solutions of our interest: P4 Medicine Regenerative Medicine Geroscience Biomarkers of Longevity AI For Longevity AgeTech Longevity NeuroTech Longevity WealthTech Longevity FinTech Longevity FemTech Reach us at info@longevitytech.fund

NaNotics LLC is developing a nanomedical platform – called NaNots – for treating major diseases – including a broad range of cancers and inflammatory disorders – via depletion from blood of specific molecules that drive or enable those diseases. NaNots are injected like a drug and clear their targets quickly, deeply and safely: typically >95% target depletion in < 5 minutes, without measurable toxicity. NaNotics is in the late preclinical stage; we are about to announce a collaboration with a major oncology center for a first-in-human study of NaNots against a soluble tumor-generated immune inhibitor, for treating cancer. The NaNotics team invented the NaNot technology, which is now the subject of 12 granted patents, with many more pending. NaNotics is based in Mill Valley, CA, just north of San Francisco.

Yale innovation has the potential to change the world. Launched by Yale University in 2022, Yale Ventures seeks to foster and accelerate a vibrant entrepreneurship and innovation ecosystem that increases support, resources, and opportunities for Yale innovators—faculty and students—as they translate their ideas and discoveries into new ventures that will positively impact the worlds greatest challenges.